Prostate Cancer Research

The Department of Urology is currently conducting research in a number of focus areas as they relate to prostate cancer. Our labs focus on three distinct research areas: 1) clinical outcomes, 2) genomic research, and 3) biomedical engineering. Our goal is to approach prostate cancer from multiple disciplines in order to reduce suffering and improve treatment outcomes for patients.

Prostate Cancer Research Areas

Researchers within the Icahn School of Medicine Department of Urology are studying the following areas in order to improve prostate cancer detection and treatment.

  • The prostate anatomy: Our group has published extensively on the prostate anatomy. Through cadaveric studies and correlation of prostatectomy specimens, we have improved outcomes related to prostate cancer surgery. This understanding of the prostate enables informed decision making during robotic prostate surgery to ensure that the cancer is removed while preserving the structures vital for sexual functioning and urinary continence. As a result, we have one of the best published outcomes of margin status and cancer control following robotic prostatectomy.

  • Development of real-time imaging utilizing multiphoton microscopy for prostate cancer: Multiphoton microscopy utilizes low energy photons to produce fluorescence in prostate tissue. This could have applications during robotic prostate surgery to identify vital structures related to quality of life and cancer control.

  • Implementation of MRI fusion imaging during prostate biopsy: Our group is one of the most experienced in the nation in utilizing MRI during prostate biopsy. We are investigating the utility of MRI and other imaging techniques to better identify the visual characteristics of aggressive prostate cancer. Our research is in clinical use where a mechanical aid is used to better target prostate cancer lesions to provide a more accurate prostate cancer diagnosis. Watch our video about next generation prostate and nerve imagine.

  • Genomic research and the development of prostate cancer biomarkers for prediction of aggressive prostate diseases: Our team has performed more than 6,500 robotic prostate cancer surgeries in the past 10 years. We are building a comprehensive resource of prostate cancer tissue and other related materials to discover the markers of aggressive prostate disease. By identifying these markers (e.g., proteins, gene mutations), we are better able to measure an individual’s disease risk, better predict disease progression, and, as a result, we can better tailor prostate cancer care.

  • Prostate cancer immunotherapy: Researchers at Mount Sinai worked to develop one of the first prostate cancer vaccines for the treatment of advanced prostate cancer. Prostate cancer vaccines utilize the body’s immune system to combat the disease.

Contact Us

625 Madison Avenue, 2nd Floor
New York, NY 10022

Tel.: 212-241-9955
Send email

null

Urology Information for International Patients